Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors

Antipsychotic agents were tested for their ability to antagonize both dopaminergic-induced and non-competitiveN-methyl-d-aspartate (NMDA) antagonist-induced behaviors. All of the agents dose-dependently antagonized the apomorphine-induced climbing mouse assay (CMA) and dizocilpine (MK-801)-induced locomotion and falling assay (MK-801-LF) with a CMA/MK-801-LF ratio of less than or equal to 1.6. However, clozapine and its structural analog olanzapine more potently antagonized MK-801-LF (1.1 and 0.05 mg/kg) than the CMA (12.3 and 0.45 mg/kg) and as a result had a CMA/MK-801-LF ratio of 11.2 and 9, respectively. Furthermore, phencyclidine (PCP) (2 mg/kg) can selectively induce social withdrawal in naive rats that were housed in pairs (familiar) for 10 days prior to testing without affecting motor activity. SCH 23390, raclopride, haloperidol, chlorpromazine and risperidone failed to reverse the social withdrawal induced by PCP up to doses which produced significant motor impairment. However, clozapine (2.5 and 5.0 mg/kg) and olanzapine (0.25 and 0.5 mg/kg) significantly reversed this social withdrawal in rats. Therefore, the non-competitive NMDA antagonists PCP and MK-801 can induce behaviors in Rodents which are selectively antagonized by clozapine and olanzapine. Furthermore, assessment of the effects of antipsychotic agents in the CMA, MK-801-LF and PCP-induced social withdrawal assays may provide a preclinical approach to identify novel agents for negative symptoms and treatment resistant schizophrenia.

[1]  R. Waziri,et al.  Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics , 1991, Biological Psychiatry.

[2]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[3]  J. Kornhuber,et al.  Presynaptic dopaminergic modulation of cortical input to the striatum. , 1986, Life sciences.

[4]  P. Burton,et al.  Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients , 2004, Psychopharmacology.

[5]  B. Moghaddam,et al.  Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. , 1993, The Journal of pharmacology and experimental therapeutics.

[6]  D. Weinberger,et al.  Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice , 2004, Psychopharmacology.

[7]  A. Imperato,et al.  NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. , 1990, European journal of pharmacology.

[8]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[9]  A. Carlsson,et al.  Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.

[10]  T. Crow,et al.  The two-syndrome concept and neuroendocrinology of schizophrenia. , 1986, The Psychiatric clinics of North America.

[11]  K. Johnson.  Phencyclidine: behavioral and biochemical evidence supporting a role for dopamine. , 1983, Federation proceedings.

[12]  A. Carlsson,et al.  The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice , 2005, Journal of Neural Transmission.

[13]  D. Segal,et al.  Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: Evidence for a dopaminergic role in some PCP-induced behaviors , 1985, Pharmacology Biochemistry and Behavior.

[14]  H. Meltzer.  Treatment of the neuroleptic-nonresponsive schizophrenic patient. , 1992, Schizophrenia bulletin.

[15]  James K. T. Wang,et al.  Presynaptic Glutamate Receptors Modulate Dopamine Release from Striatal Synaptosomes , 1991, Journal of neurochemistry.

[16]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[17]  S. Iversen.  Is it possible to model psychotic states in animals? , 1987, Journal of psychopharmacology.

[18]  W. Schmidt,et al.  MK-801-induced stereotypy and its antagonism by neuroleptic drugs , 2005, Journal of Neural Transmission / General Section JNT.

[19]  D. Grandy,et al.  Molecular biology of the dopamine receptors. , 1991, European journal of pharmacology.

[20]  H. Hartman,et al.  Effects of atypical antipsychotic agents on social behavior in rodents , 1993, Pharmacology Biochemistry and Behavior.

[21]  A. Verma,et al.  Modulation of MK-801 response by dopaminergic agents in mice , 2005, Psychopharmacology.

[22]  S. Deutsch,et al.  A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. , 1989, Clinical neuropharmacology.

[23]  S. Sesack,et al.  In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other , 1990, Brain Research.

[24]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.

[25]  J. Kane,et al.  Do Negative Symptoms Respond to Pharmacological Treatment? , 1989, British Journal of Psychiatry.

[26]  P. Seeman.  Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[27]  B. Costall,et al.  Mesolimbic involvement with behavioural effects indicating antipsychotic activity. , 1974, European journal of pharmacology.

[28]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[29]  Kenneth M. Johnson,et al.  Glycine potentiates N-methyl-d-aspartate-induced [3H]TCP binding to rat cortical membranes , 1987, Neuroscience Letters.

[30]  B. Costall,et al.  Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. , 1978, European journal of pharmacology.

[31]  W. Freed,et al.  Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice , 1984, Neuropharmacology.

[32]  F. Colpaert,et al.  The phencyclidine (PCP) analog N-[1-(2-benzo(B)thiophenyl) cyclohexyl]piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801. , 1989, The Journal of pharmacology and experimental therapeutics.

[33]  C. R. Gardner,et al.  A social interaction model of anxiety sensitive to acutely administered benzodiazepines , 1984 .

[34]  J. Kane,et al.  Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial , 1989, Psychopharmacology.

[35]  J. Woods,et al.  The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[36]  N. Moore,et al.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. , 1992, The Journal of pharmacology and experimental therapeutics.